Actrii proteins and use in treating post-capillary pulmonary hypertension
AssigneeAcceleron Pharma Inc.
InventorsGang Li, Ravindra Kumar, Jonathan Toshi Lu, Sachindra Joshi, Patrick Andre
Life of this patent
Estimating the term…
Abstract
In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.
Claims22
A method of treating combined pre- and postcapillary pulmonary hypertension (Cpc-PH) due to heart failure with preserved ejection fraction (HFpEF) in a apatient, comprising administering to the patient an effective amount of a fusion protein comprising:
- (i) an ActRII polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2;
- (ii) an Fc domain comprising an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:
- 32;
- and
- (iii) a linker domain positioned between the ActRII polypeptide and the Fc domain.
Dependencies are inferred from the claim text.